Impact of histological variants on oncological outcomes of patients with urothelial carcinoma of the bladder treated with radical cystectomy
Évanguelos Xylinas(NewYork–Presbyterian Hospital), Shahrokh F. Shariat(Universitätszahnklinik Wien), Luis A. Kluth(Goethe University Frankfurt), Yair Lotan(Southwestern Medical Center), A. Brisuda(Charles University), Marc Zerbib(Université Paris Cité), Douglas S. Scherr(Cornell University), Brian D. Robinson(Cornell University), Michael Rink(Marienkrankenhaus Hamburg), Yves Fradet(Centre hospitalier universitaire de Québec), Talia Faison(Cornell University), David A. Green(Columbia University), Richard K. Lee(NewYork–Presbyterian Hospital), Pierre I. Karakiewicz(Université de Montréal), Armin Pycha(Sigmund Freud Privatuniversität Wien), Marek Babjuk(Charles University)
Cited by 170
Related Papers
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2021|645
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines
|European Urology|2023|618
Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up
|Annals of Oncology|2019|484
Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC)
|World Journal of Urology|2016|471